TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs
Brief Summary: This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.


Options:
A: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
B: Arm Label: Placebo (for Rilonacept) and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Other: Placebo (for Rilonacept) | Arm Label: Rilonacept and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Drug: Indomethacin | Arm Label: Rilonacept and Placebo (for Indomethacin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Other: Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): Rilonacept and Indomethacin, Rilonacept and Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin, Rilonacept and Indomethacin | Intervention Type: OTHER; Name: Placebo (for Indomethacin); Assigned to Arm(s): Rilonacept and Placebo (for Indomethacin) | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg
D: Arm Label: crFMF: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: crCMF: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HIDS/MKD: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: HIDS/MKD: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: TRAPS: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: TRAPS: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): HIDS/MKD: 150 mg, TRAPS: 150 mg, crFMF: 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): HIDS/MKD: placebo, TRAPS: placebo, crCMF: placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs
Brief Summary: This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.


Options:
A: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
B: Arm Label: crFMF: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: crCMF: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HIDS/MKD: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: HIDS/MKD: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: TRAPS: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: TRAPS: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): HIDS/MKD: 150 mg, TRAPS: 150 mg, crFMF: 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): HIDS/MKD: placebo, TRAPS: placebo, crCMF: placebo
C: Arm Label: once daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Arm Label: twice daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Intervention Type: DRUG; Name: colchicine; Assigned to Arm(s): once daily dosage schema of colchicine, twice daily dosage schema of colchicine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Wait-list Controlled Trial of a Qigong Intervention Program on Telomerase Activity and Psychological Stress in Abused Chinese Women
Brief Summary: The purpose of this study is to evaluate the effect of a qigong intervention program on telomerase activity in Chinese women with a history of intimate partner violence.


Options:
A: Arm Label: Strength at Home Couples Group; Type: EXPERIMENTAL; Interventions: Behavioral: Strength at Home Couples Group | Arm Label: Supportive Group Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Group Therapy | Intervention Type: BEHAVIORAL; Name: Strength at Home Couples Group; Assigned to Arm(s): Strength at Home Couples Group | Intervention Type: BEHAVIORAL; Name: Supportive Group Therapy; Assigned to Arm(s): Supportive Group Therapy
B: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program
C: Arm Label: Qigong training; Type: EXPERIMENTAL; Interventions: Behavioral: Qigong training | Arm Label: Wait-list control- Health talks; Type: OTHER; Interventions: Other: Wait-list control- Health talks | Intervention Type: BEHAVIORAL; Name: Qigong training; Assigned to Arm(s): Qigong training | Intervention Type: OTHER; Name: Wait-list control- Health talks; Assigned to Arm(s): Wait-list control- Health talks
D: Arm Label: Multimedia HIV/STI prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Multimedia WORTH | Arm Label: Traditional HIV/STI prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional WORTH | Arm Label: Wellness Promotion; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wellness Promotion | Intervention Type: BEHAVIORAL; Name: Multimedia WORTH; Assigned to Arm(s): Multimedia HIV/STI prevention | Intervention Type: BEHAVIORAL; Name: Traditional WORTH; Assigned to Arm(s): Traditional HIV/STI prevention | Intervention Type: BEHAVIORAL; Name: Wellness Promotion; Assigned to Arm(s): Wellness Promotion

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Wait-list Controlled Trial of a Qigong Intervention Program on Telomerase Activity and Psychological Stress in Abused Chinese Women
Brief Summary: The purpose of this study is to evaluate the effect of a qigong intervention program on telomerase activity in Chinese women with a history of intimate partner violence.


Options:
A: Arm Label: Qigong training; Type: EXPERIMENTAL; Interventions: Behavioral: Qigong training | Arm Label: Wait-list control- Health talks; Type: OTHER; Interventions: Other: Wait-list control- Health talks | Intervention Type: BEHAVIORAL; Name: Qigong training; Assigned to Arm(s): Qigong training | Intervention Type: OTHER; Name: Wait-list control- Health talks; Assigned to Arm(s): Wait-list control- Health talks
B: Arm Label: Written Exposure Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Exposure Therapy | Arm Label: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder; Type: EXPERIMENTAL; Interventions: Behavioral: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder | Intervention Type: BEHAVIORAL; Name: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder; Assigned to Arm(s): Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder | Intervention Type: BEHAVIORAL; Name: Written Exposure Therapy; Assigned to Arm(s): Written Exposure Therapy
C: Arm Label: CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD | Arm Label: Imagery Rehearsal Therapy + CBT for PTSD; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD, Behavioral: Imagery Rehearsal Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for PTSD; Assigned to Arm(s): CBT for PTSD, Imagery Rehearsal Therapy + CBT for PTSD | Intervention Type: BEHAVIORAL; Name: Imagery Rehearsal Therapy; Assigned to Arm(s): Imagery Rehearsal Therapy + CBT for PTSD
D: Arm Label: Motivational Interviewing (MI); Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing (MI) | Intervention Type: BEHAVIORAL; Name: Motivational interviewing (MI); Assigned to Arm(s): Motivational Interviewing (MI)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endometrial Receptivity Enhancement Through Induced Injury and Repair During Ovarian Stimulation in an Antagonist Down-regulated Cycle
Brief Summary: A randomised controlled open-label clinical trial to assess the effect of artificially induced endometrial injury and repair during ovarian stimulation on the clinical pregnancy rate of an antagonist downregulated in-vitro fertilisation cycle


Options:
A: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induced endometrial injury arm; Type: EXPERIMENTAL; Interventions: Device: Pipelle de Cornier® | Intervention Type: DEVICE; Name: Pipelle de Cornier®; Assigned to Arm(s): Induced endometrial injury arm
B: Arm Label: Comprehensive Chromosome Screening; Type: EXPERIMENTAL; Interventions: Other: Comprehensive Chromosome Screening | Arm Label: No Comprehensive Chromosome Screening; Type: PLACEBO_COMPARATOR; Interventions: Other: Morphologically Best | Intervention Type: OTHER; Name: Comprehensive Chromosome Screening; Assigned to Arm(s): Comprehensive Chromosome Screening | Intervention Type: OTHER; Name: Morphologically Best; Assigned to Arm(s): No Comprehensive Chromosome Screening
C: Arm Label: Control - Standard ART treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test - PGS; Type: EXPERIMENTAL; Interventions: Genetic: Next Generation Sequencing after Blastocyst biopsy | Intervention Type: GENETIC; Name: Next Generation Sequencing after Blastocyst biopsy; Assigned to Arm(s): Test - PGS
D: Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus - A Multi-center Evaluation of Health-related Quality of Life Assessments and Biomarkers of Exposure and Harm
Brief Summary: To evaluate selected biomarkers of tobacco exposure and biomarkers of harm and assess quality of life measures in smokers randomly switched from their usual brand of cigarette to one of three test products: (1) a tobacco-heating cigarette; (2) snus (smokeless tobacco); or (3) an ultra-low machine yield tobacco-burning cigarette.


Options:
A: Arm Label: THS 2.2 Menthol (mTHS 2.2); Type: EXPERIMENTAL; Interventions: Other: THS 2.2 Menthol (mTHS 2.2) | Arm Label: Menthol Conventional Cigarette (mCC); Type: ACTIVE_COMPARATOR; Interventions: Other: Menthol Conventional Cigarette (mCC) | Arm Label: Smoking abstinence (SA); Type: SHAM_COMPARATOR; Interventions: Other: Smoking Abstinence (SA) | Intervention Type: OTHER; Name: THS 2.2 Menthol (mTHS 2.2); Assigned to Arm(s): THS 2.2 Menthol (mTHS 2.2) | Intervention Type: OTHER; Name: Menthol Conventional Cigarette (mCC); Assigned to Arm(s): Menthol Conventional Cigarette (mCC) | Intervention Type: OTHER; Name: Smoking Abstinence (SA); Assigned to Arm(s): Smoking abstinence (SA)
B: Arm Label: THS 2.2; Type: EXPERIMENTAL; Interventions: Other: THS 2.2 | Arm Label: CC; Type: ACTIVE_COMPARATOR; Interventions: Other: CC | Intervention Type: OTHER; Name: THS 2.2; Assigned to Arm(s): THS 2.2 | Intervention Type: OTHER; Name: CC; Assigned to Arm(s): CC
C: Arm Label: Tobacco-Heating Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Heating Cigarette | Arm Label: Snus (Smokeless Tobacco); Type: EXPERIMENTAL; Interventions: Other: Snus (Smokeless Tobacco) | Arm Label: Tobacco-Burning Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Burning Cigarette | Intervention Type: OTHER; Name: Tobacco-Heating Cigarette; Assigned to Arm(s): Tobacco-Heating Cigarette | Intervention Type: OTHER; Name: Snus (Smokeless Tobacco); Assigned to Arm(s): Snus (Smokeless Tobacco) | Intervention Type: OTHER; Name: Tobacco-Burning Cigarette; Assigned to Arm(s): Tobacco-Burning Cigarette
D: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants
Brief Summary: This study will assess the efficacy, safety, and immunogenicity of a 3-dose regimen of RotaTeq™ (V260) in healthy Chinese infants. Approximately 4040 participants at least 6 weeks and up to 12 weeks of age at the time of the first vaccination with V260 or placebo will be enrolled and randomized (1:1) to receive either V260 or placebo. Participants will also receive the routine China Expanded Program on Immunization (EPI) vaccines (oral poliovirus vaccine \[OPV\] and diphtheria, tetanus, and acellular pertussis vaccine \[DTaP\]) either staggered or concomitantly with V260 or placebo. All participants will be followed for efficacy and safety. Immune responses to OPV and DTaP will be evaluated in a subset of participants. The primary hypothesis of the study states that V260 will be efficacious in preventing any severity of rotavirus gastroenteritis as compared with placebo.


Options:
A: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI
B: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants
Brief Summary: This study will assess the efficacy, safety, and immunogenicity of a 3-dose regimen of RotaTeq™ (V260) in healthy Chinese infants. Approximately 4040 participants at least 6 weeks and up to 12 weeks of age at the time of the first vaccination with V260 or placebo will be enrolled and randomized (1:1) to receive either V260 or placebo. Participants will also receive the routine China Expanded Program on Immunization (EPI) vaccines (oral poliovirus vaccine \[OPV\] and diphtheria, tetanus, and acellular pertussis vaccine \[DTaP\]) either staggered or concomitantly with V260 or placebo. All participants will be followed for efficacy and safety. Immune responses to OPV and DTaP will be evaluated in a subset of participants. The primary hypothesis of the study states that V260 will be efficacious in preventing any severity of rotavirus gastroenteritis as compared with placebo.


Options:
A: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI
C: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet and Prevention of Ischemic Heart Disease: a Translational Approach
Brief Summary: The objective of this study is to test the effect of substitution dietary guidelines that are specifically aimed at the prevention of ischemic heart disease (IHD) on the dietary intake in the general Danish population.


Options:
A: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
B: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
C: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet and Prevention of Ischemic Heart Disease: a Translational Approach
Brief Summary: The objective of this study is to test the effect of substitution dietary guidelines that are specifically aimed at the prevention of ischemic heart disease (IHD) on the dietary intake in the general Danish population.


Options:
A: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
B: Arm Label: Diet: Dietary Advice; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: General Advice | Arm Label: Low glycemic index Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low Glycemic Index Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Glycemic Index Mediterranean Diet; Assigned to Arm(s): Low glycemic index Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: General Advice; Assigned to Arm(s): Diet: Dietary Advice
C: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A
D: Arm Label: low-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-fat diet | Arm Label: moderate-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: moderate-fat diet | Arm Label: high-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: high-fat diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate-fat diet; Assigned to Arm(s): moderate-fat diet | Intervention Type: BEHAVIORAL; Name: high-fat diet; Assigned to Arm(s): high-fat diet

Answer: A